1 / 14

Title of Presentation

Title of Presentation. Opportunities for future EU-ASEAN collaborations in Health in Horizon 2020 Tom Crawley, British High Commission Singapore. EU-ASEAN S&T cooperation to jointly tackle societal challenges. Health in Horizon 2020. Societal Challenge 1: Health, Demographic Change and

woods
Download Presentation

Title of Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Title of Presentation Opportunities for future EU-ASEAN collaborations in Health in Horizon 2020 Tom Crawley, British High Commission Singapore EU-ASEAN S&T cooperation to jointly tackle societal challenges UNCLASSIFIED

  2. Health in Horizon 2020 Societal Challenge 1: Health, Demographic Change and Well-being • Indicative total budget of EUR 7.47 billion - though other societal challenges also have a relationship to health • Addressing European and global challenges: aging populations, increasing burdens of disease, pressures on health care sector and systems

  3. Health in Horizon 2020 Health in 2014/15 • Total budget for 2014/15 calls is EUR 1.2 bn • 34 topics in Personalising Health and Care, and 16 Co-ordination Activities • PHC includes seven topics; understanding health, improved health information, prevention, diagnosis, treatment, active and health aging, and integrated and citizen-centered care

  4. Health in Horizon 2020 International Cooperation Possibilities in Health in Horizon 2020 • PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co- operation for environment and health based interventions • PHC 7-2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens • PHC 8-2014: Vaccine development for poverty-related infectious diseases- TB • PHC 9-2015: Vaccine development for poverty-related infectious diseases- HIV/AIDS • HCO 4-2014: Support for international infectious disease preparedness research • PHC 14-2015: New Therapies for Rare Diseases • HCO 5 – 2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes • HCO 5 – 2014: Global Alliance for Chronic Diseases: 2015 priority

  5. Health in Horizon 2020 PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector cooperation for environment and health based interventions • Specific Challenge: Targeting ‘health in all policies’ to foster environments which support health, well-being and behavioural change. • Scope: Limited to the integration of environment, climate and health sectors (including air quality, water and sanitation, chemicals, occupational factors, etc.). Proposals should develop inter-sector initiatives and/or policy initiatives to promote health or prevent disease based on known environmental stressors. • Impact: Evidence on effective interventions, impact on sustainability of healthcare systems. • Evaluation: Two Stage • Budget: EUR 4-6 million per proposal, total budget of EUR 18 million

  6. Health in Horizon 2020 PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens • Specific challenge: Threat of epidemics caused by existing, new and emerging infectious diseases (including from antimicrobial resistant pathogens), many of which are zoonoses, necessitating a “one health” approach • Scope: Sequence based data for pathogens will be generated, stored and analysed in combination with clinical, microbiological, epidemiological and other data needed for risk assessment (RA) • Expected Impact: Better containment and mitigation of epidemics by competent authorities on the basis of a shared information system and global standards for rapid pathogen identification. • Evaluation: Single Stage + Hearing • Budget: One project with a budget of EUR 15-20 million (incl. 5 from SC2)

  7. Health in Horizon 2020 PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis • Specific challenge: Many poverty-related and neglected infectious diseases continue to escape attempts to develop effective vaccines against them. • Scope: Proposals will focus on strengthening the capacity for discovery and early development of new vaccine candidates for tuberculosis by i) establishing a platform for the identification of (at least 10) new diverse and novel vaccine candidates for tuberculosis, and their pre-clinical and early clinical testing, and ii) addressing major bottlenecks in vaccine development; in particular better ways for early distinction between successful candidates and those that will eventually fail in late stage clinical trials. • Expected Impact: Reduction in cost associated with late stage vaccine failure, increasing number of other candidates which can be tested with same resources, links to EDCTP. • Evaluation: Single Stage + Hearing. Deadline 15th April 2014 at 17.00.00 Brussels time. • Budget: One project with a budget of up to EUR 25 million

  8. Horizon 2020 Health Calls PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases – HIV/AIDS • Specific challenge: Many poverty-related and neglected infectious diseases continue to escape attempts to develop effective vaccines against them • Scope: Proposals will focus on strengthening the capacity for discovery and early development of new vaccine candidates for tuberculosis by i) establishing a platform for the identification of (at least 10) new diverse and novel vaccine candidates for tuberculosis, and their pre-clinical and early clinical testing, and ii) addressing major bottlenecks in vaccine development; in particular better ways for early distinction between successful candidates and those that will eventually fail in late stage clinical trials. • Expected Impact: Reduction in cost associated with late stage vaccine failure, increasing number of other candidates which can be tested with same resources, links to EDCTP. • Evaluation: Single Stage + Hearing. • Budget: Expected to be one project with a budget of EUR 21 million

  9. Horizon 2020 Calls HCO 4-2014: Support for internationalinfectious disease preparedness research • Specific challenge: Human health threatened by potential epidemics caused by existing, new and emerging infectious diseases (including from antimicrobial resistant pathogens). In order to save lives, the research response needs to be quick, flexible, comprehensive and global. • Scope: The support action should provide organisational support to the implementation of the global research collaboration for infectious diseases preparedness consortium (GloPID-R), • Expected Impact: Reinforced international cooperation in funding of research in new and emerging infectious diseases aiming to ensure a rapid and effective research response in case of an outbreak. • Evaluation: Single Stage. Deadline 15th April 2014 at 17.00 Brussels Time. • Budget: One project of EUR 3 million

  10. Horizon 2020 Health Calls PHC 14 – 2015: New therapies for rare diseases • Specific challenge: 6000-8000 rare diseases are lacking therapies despite many diseases being life-threatening or chronically debilitating. • Scope: Proposals may address one or more of the following: development of new or improved therapeutic approaches, for repurposing of existing therapies, as well as for preclinical research, animal model development and good manufacturing practice (GMP) production. Selected proposals should contribute to the objectives of, and follow the guidelines and policies of the International Rare Diseases Research Consortium, IRDiRC. • Expected Impact: Proposals should contribute to reaching the IRDiRC objective to deliver 200 new therapies for rare diseases by 2020. • Evaluation: Two stage • Budget: Projects of EUR 4-6 million, with a total budget of EUR 60 million

  11. Health in Horizon 2020 HCO 5 – 2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes • Specific challenge: It is currently estimated that 347 million people worldwide suffer from diabetes with more than 80% from low-and middle-income countries. Halting the rise in prevalence of diabetes has been identified as one of the 9 WHO non communicable diseases global voluntary targets to be met by Member States by 2025. • Scope: Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of type 2 diabetes in low and middle income countries, and in vulnerable populations in high income countries. • Expected Impact: Reducing health inequalities and inequities, including gender, in the prevention and treatment of type 2 diabetes in both a local and global context. • Evaluation: Single stage, deadline 15th April 2014 at 17.00.00 Brussels time • Budget: Projects of EUR 1 to 3 million, with a total budget of EUR 9 million

  12. Health in Horizon 2020 HCO 5 – 2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes • Specific challenge: It is currently estimated that 347 million people worldwide suffer from diabetes with more than 80% from low-and middle-income countries. Halting the rise in prevalence of diabetes has been identified as one of the 9 WHO non communicable diseases global voluntary targets to be met by Member States by 2025. • Scope: Proposals should generate new knowledge on interventions and their implementation for the prevention and treatment of type 2 diabetes in low and middle income countries, and in vulnerable populations in high income countries. • Expected Impact: Reducing health inequalities and inequities, including gender, in the prevention and treatment of type 2 diabetes in both a local and global context. • Evaluation: Single stage, deadline 15th April 2014 at 17.00.00 Brussels time • Budget: Projects of EUR 1 to 3 million, with a total budget of EUR 9 million

  13. Health in Horizon 2020 HCO 6 – 2015: Global Alliance for Chronic Diseases: 2015 priority • Specific challenge: ?? • Scope: ?? • Expected Impact: ?? • Evaluation: Single stage • Budget: Projects of EUR 1 to 3 million, with a total budget of EUR 12 million

  14. Health in Horizon 2020 Summary • Join the TB Vaccine workshop this afternoon from 13.00 in room 405 • Also keeen to explore work on: • Environment and health based interventions • HIV vaccines • Emerging infectious disease • Antimicrobial resistance • Non-communicable diseases

More Related